June 8, 2020 / 11:12 AM / 24 days ago

BRIEF-CASI Pharma Submits Application To Conduct Study For Antibody Program

June 8 (Reuters) - CASI Pharmaceuticals Inc:

* CASI PHARMACEUTICALS ANNOUNCES SUBMISSION OF CLINICAL TRIAL APPLICATION (IND) TO CONDUCT PHASE 1 STUDY FOR ANTI-38 MONOCLONAL ANTIBODY PROGRAM

* CASI PHARMACEUTICALS INC - TARGETING STUDY INITIATION IN LATE 2020 OR EARLY 2021 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below